Janssen Korea has decided not to file a lawsuit for canceling a drug price cut and a request for suspension of execution following the appeal in a patent dispute. It is interpreted as an intention to avoid controversy over the abuse of the suspension system related to the so-called 'Drug Price Reduction and Refund Act' that recently passed the National Assembly. Janssen Korea Opsumit Patent Dispute Appeal Decision. "We will not proceed with the lawsuit to cancel the drug price reduction"

According to Janssen Korea on the 19th, the company decided to appeal to the Patent Court in a dispute with Samjin Pharmaceutical over the Opsumit composition patent. This dispute was sparked by Samjin's request for a pass